Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Long-Term Debt Repayments (2019 - 2020)

aTYR PHARMA's Long-Term Debt Repayments history spans 2 years, with the latest figure at $3.1 million for Q4 2020.

  • For Q4 2020, Long-Term Debt Repayments rose 54.15% year-over-year to $3.1 million; the TTM value through Dec 2020 reached $9.1 million, up 13.54%, while the annual FY2020 figure was $9.1 million, 13.54% up from the prior year.
  • Long-Term Debt Repayments reached $3.1 million in Q4 2020 per ATYR's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $3.1 million in Q4 2020 to a low of $2.0 million in Q1 2019.